CompletedNot Applicable

Autologous Platelet-rich Plasma as a Treatment for Macular Holes

Colombia13 participantsStarted 2022-10-25

Plain-language summary

For a series of patients with full-thickness macular hole, an autologous plasma rich in growth factors was developed in the form of a clot and applied to the retinal defect. These patients were followed up for a period of one year, obtaining substantial improvement both anatomically and functionally.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with a diagnosis of macular hole with a total thickness greater than 400 microns * Patients without prior vitreoretinal surgery * Patients over 18 years of age Exclusion Criteria: * Patients under 18 years of age * Patients with previous vitreoretinal surgery * Patients who had other additional retinal pathologies (diabetic retinopathy, hypertensive retinopathy, vascular retinal occlusions, retinal detachment, etc.)

What they're measuring

Macular hole closure

Timeframe: Follow-up was carried out for 1 year

Trial details

NCT IDNCT06323902

SponsorClinica Oftalmologica Paredes

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06-08

View on ClinicalTrials.gov More Macular Holes trials